findmyKOL
Clinical trialNCT04093167Active, not recruitingPhase 2/PHASE3Interventional

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

SponsorCanadian Cancer Trials GroupEnrollment53Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pembrolizumab before they feel worse, or the cancer is worse on imaging tests. Researchers are studying how levels of these biomarkers can show how cancers are responding to treatment and whether adding chemotherapy to pembrolizumab based on detection of ctDNA can offer better results.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Bcca - Vancouver

    Vancouver, British Columbia, Canada

  • Health Sciences North

    Greater Sudbury, Ontario, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Algoma District Cancer Program

    Sault Ste. Marie, Ontario, Canada

  • University Health Network

    Toronto, Ontario, Canada

  • the Jewish General Hospital

    Montreal, Quebec, Canada

United States
  • the University of Chicago Medical Center

    Chicago, Illinois, United States

  • the Sidney Kimmel Comprehensive Cancer Centre

    Baltimore, Maryland, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 May 2020
Primary completion
31 Dec 2026
Completion
30 Jul 2027
Last update posted
31 Jul 2026
Registered enrollment
53
Registry id
NCT04093167
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.